本土传统药企出手!正大天晴母公司拟以5亿美元并购礼新医药

第一财经
15 Jul

过去,在并购中国本土生物科技企业上,主要以跨国药企居多,中国本土传统药企出手的寥寥无几。7月15日晚间,正大天晴母公司中国生物制药(01177.HK)宣布,将以约5亿美元的净代价100%收购礼新医药科技(上海)有限公司。收购完成后,礼新医药将成为中国生物制药全资子公司。在中国生物制药收购之前,礼新医药已开展了两笔总额近40亿美元的授权交易,其中一笔发生于2024年11月,礼新医药以8.88亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10